Acarbose Drug Asset Due Diligence Report 2026

This Acarbose Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

188

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Acarbose can convert its Small molecule drug profile and AMYs x GANC x MGAM x α-glucosidase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Acarbose (query alias: Acarbose)
Modality / target	Small molecule drug; AMYs x GANC x MGAM x α-glucosidase; Alpha amylases inhibitors, GANC inhibitors, MGAM inhibitors
Highest global status	Approved
Originator	Bayer AG
Active developers	Bayer Yakuhin Ltd., Bayer HealthCare AG, Arrotex Pharmaceuticals Pty Ltd.

The MCP disease footprint includes Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2500108461	Phase 4	Not yet recruiting	100	HbA1c
CTRI/2025/09/095419	Phase 2/3	Not Yet Recruiting	274	Not disclosed
NCT07436585	Phase 1	Completed	170	Daily pain AUC

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study

Phase 2; n=28; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 2 Participants ; Other (Not Including Serious) Adverse Events = 3 Participants ; -

Comparison of glucose fluctuation between metformin combined with acarbose or sitagliptin in Chinese patients with type 2 diabetes: A multicenter, randomized, active-controlled, open-label, parallel design clinical trial

Phase 4; n=701; evaluation: Positive. Reported fields: Time below range(<3.9 mmol/L) = 0.78 % ; Time below range(<3.9 mmol/L) = 0.45 %

Growth differentiation factor 15 is not associated with glycemic control in patients with type 2 diabetes mellitus treated with metformin: a post-hoc analysis of AIM study.

Phase 4; n=not disclosed; evaluation: not stated. Reported fields: GDF15 levels(serum) = 920.60(701.45 - 1332.55) pg/mL ; GDF15 levels(serum) = 936.70(741.00 - 1205.40) pg/mL

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Acarbose addresses Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2015-12-21	中美华东出资受让迈华替尼新药技术和阿卡波糖咀嚼片新药技术的关联交易公告	IND Application	US$11.6M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Acarbose tablet as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Method for recovering acarbose from acarbose recovery liquid”. The milestone feed surfaced a patent-application signal described as “Method for extracting and purifying acarbose”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO